Scientists test 'Kill Switch' in Cancer-Fighting immune cells
NCT ID NCT03696784
Summary
This early-stage study is testing the safety of a new type of personalized cell therapy for adults with B-cell lymphoma that has come back or not responded to other treatments. Doctors take a patient's own immune cells (T cells), modify them in a lab to better target cancer, and add a special 'safety switch' that can be turned on if severe side effects occur. The main goal is to find a safe dose and see if the safety switch works to manage potential side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.